EUVIMEDEUVIMED entdecken
Crossref

Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC)

Vikram Pothuri, Jorge G Zárate Rodriguez, Christina Kasting, Natasha Leigh, William G Hawkins, Dominic E Sanford, Ryan C Fields

HPB · 2023-12 · 25 (12) · 1545-1554

DOI: 10.1016/j.hpb.2023.08.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HPB, 2023-12. Verfasst von Vikram Pothuri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NCATS NIH HHS, NCI NIH HHS, Alvin J. Siteman Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The impact of neighborhood deprivation on outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) is not well-described and represents an area to improve disparities. METHODS: We retrospectively queried our prospectively maintained database of patients with PDAC (2014-2022). Patients were grouped by Area Deprivation Index (ADI) and rural-urban commuting area (RUCA) codes. Cox proportional hazards models and logistic regressions were used to investigate effect on overall survival (OS) and adjuvant therapy administration. RESULTS: 536 patients were included. High ADI patients (more disadvantaged, n = 184) were more likely to identify as non-Hispanic Black (17.9% vs. 4.8%, p < 0.01) and were more likely to be from rural areas (49.5% vs. 18.5%, p < 0.01). High ADI was independently associated with decreased OS (HR (95% CI): 1.31 (1.01-1.69), p = 0.04). Urban high ADI patients were 3.5 times more likely to receive adjuvant therapy than rural high ADI patients (OR [95% CI]: 3.48 [1.26-9.61], p = 0.02). CONCLUSION: Patients from the most disadvantaged neighborhoods have decreased OS. Access to adjuvant therapy likely contributes to this disparity in rural areas. Investigation into sources of this OS disparity and identification of barriers to adjuvant therapy will be crucial to improve outcomes in underserved patients with PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansRetrospective StudiesCombined Modality Therapy

Autor:innen und Institutionen

  • Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA; Alvin J. Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA; Alvin J. Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic add…

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • Alvin J. Siteman Cancer Center
  • National Cancer Institute

Zitieren

APA

Pothuri, V., Zárate Rodriguez, J. G., Kasting, C., Leigh, N., Hawkins, W. G., Sanford, D. E., & Fields, R. C. (2023). Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC). HPB, 25(12), 1545-1554. https://doi.org/10.1016/j.hpb.2023.08.005

Vancouver

Pothuri V, Zárate Rodriguez JG, Kasting C, Leigh N, Hawkins WG, Sanford DE, et al. Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC). HPB. 2023;25(12):1545-1554. doi:10.1016/j.hpb.2023.08.005

BibTeX
@article{Pothuri2023,
  author = {Pothuri, Vikram and Zárate Rodriguez, Jorge G and Kasting, Christina and Leigh, Natasha and Hawkins, William G and Sanford, Dominic E and Fields, Ryan C},
  title = {Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC)},
  journal = {HPB},
  year = {2023},
  volume = {25},
  number = {12},
  pages = {1545--1554},
  doi = {10.1016/j.hpb.2023.08.005}
}
Kostenlos starten →